Instituto Nacional de Enfermedades Neoplasicas INEN

Lima Lima 34

0 studies enrolling now · 2 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Non-Small-Cell Lung Carcinoma, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer — Completed